Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

# Subtle executive deficits are associated with higher brain amyloid burden and lower cortical volume in subjective cognitive decline: the FACEHBI cohort

## Abstract

To determine whether lower performance on executive function tests in subjective cognitive decline (SCD) individuals are associated with higher levels of brain amyloid beta (Aβ) deposition and regional volumetric reduction in areas of interest for Alzheimer’s disease (AD). 195 individuals with SCD from the FACEHBI study were assessed with a neuropsychological battery that included the following nine executive function tests: Trail Making Test A and B (TMTA, TMTB), the Rule Shift Cards subtest of BADS, the Automatic Inhibition subtest of the Syndrom Kurz Test (AI-SKT), Digit Span Backwards and Similarities from WAIS-III, and the letter, semantic, and verb fluency tests. All subjects underwent an 18F-Florbetaben positron emission tomography (FBB-PET) scan to measure global standard uptake value ratio (SUVR), and a magnetic resonance imaging (MRI). A multiple regression analysis, adjusted for age, was carried out to explore the association between global SUVR and performance on executive tests. Then, on those tests significantly associated with amyloid burden, a voxel-based morphometry (VBM) analysis was carried out to explore their correlates with grey matter volume. Multiple regression analysis revealed a statistically significant association between Aβ deposition and performance on one of the executive tests (the AI-SKT). Moreover, VBM analysis showed worse AI-SKT scores were related to lower volume in bilateral hippocampus and left inferior frontal regions. In conclusion, in SCD individuals, worse automatic inhibition ability has been found related to higher cerebral Aβ deposition and lower volume in the hippocampus and frontal regions. Thus, our results may contribute to the early detection of AD in individuals with SCD.

## Introduction

Subjective cognitive decline (SCD) refers to the self-perception of worsening of memory or other cognitive functions without objective impairment on existing standardized cognitive tests1,2. Cross-sectional studies in normal aging support SCD’s association with Alzheimer’s disease–related (AD) biomarker abnormalities such as amyloid burden3,4, reduced hippocampal volume5,6 and regional brain hypometabolism7,8. Moreover, longitudinal studies have demonstrated that individuals with SCD have an increased annual risk of conversion to mild cognitive impairment (MCI) and dementia2,9.

Several studies have found lower performance on episodic memory tests related to higher brain amyloid burden in cognitively healthy older adults10,11,12. However, memory does not seem the only cognitive function suffering an early decline in preclinical AD. Executive function performance can predict conversion to cognitive impairment13,14,15,16 and become an early sign of AD17,18.

Neuroimaging studies in healthy elderly have reported worse performance on executive tests associated with lower grey matter (GM) volume in frontal areas19. Lower volume in neocortical regions, such as the orbitofrontal, posterior cingulate and precuneus, correlates with higher amyloid burden in SCD, but not in healthy controls or in patients with MCI or AD dementia20. A recent study demonstrated that those individuals from a population-based cohort who presented more self-reporting cognitive decline had lower GM volume in known AD-related areas21.

The work presented herein is part of the Fundació ACE Healthy Brain Initiative (FACEHBI)22, a broad study based on a cohort of 200 middle-aged adults with SCD and focused on increasing the understanding of AD’s preclinical stages. It is a longitudinal study involving a multimodal biomarker approach intended to capture the more relevant molecular, structural and functional processes present in the earliest phases of AD combined with a comprehensive and sensitive neuropsychological protocol.

A better understanding of the relationship between AD biomarkers and objective cognitive performance in SCD is an active line of research. A previous study from our group using data from the FACEHBI cohort12 found that worse performance on the Face-Name Associative Memory test was related to higher amyloid beta (Aβ) deposition in individuals with SCD. Similarly, Amariglio et al.3 reported a significant association between higher Aβ deposition and worse performance on episodic and working memory tests. Since previous studies in cognitively healthy individuals have demonstrated that executive deficits can precede other cognitive ones, such as memory18,23, we decided to focus on executive functioning.

The concept of executive function includes a series of cognitive processes, such as impulse control, response inhibition, working memory, cognitive flexibility, planning, judgment and decision-making, which facilitate achieving a specific goal24,25. This current work focuses on determining whether or not a relationship exists between performance in a series of executive tests and AD biomarkers. In the present study, we hypothesized that executive function tests may be a useful tool to detect subtle cognitive deficits related to AD biomarkers in SCD individuals. The aims of this study were (1) to determine whether lower performance on executive function tests in subjective cognitive decline (SCD) individuals are associated with higher levels of brain Aβ deposition; and (2) in those executive function tests correlated with amyloid burden, to elucidate if worse performance is associated with a specific GM topology in regions known to be sensitive to AD.

## Results

### Sociodemographic and clinical data

The sociodemographic and clinical characteristics of 195 study participants with SCD are detailed in Table 1.

### Correlations between Aβ deposition and executive function performance

Multiple regression analysis was performed using as an outcome the global SUVR. Predictors of the model were all executive function variables of the study: Rule Shift Cards from BADS, Digit Span Backwards and Similarities from WAIS-III, Trail Making Test A and B, Automatic Inhibition subtest of the Syndrome Kurz Test (AI-SKT), and letter, semantic and verb fluency tests. Age was included in the model as an adjusting variable because it is the only demographic variable (age, sex, years of formal education) that obtained a statistically significant association with global SUVR (r = 0.21, p = 0.003). Under a stepwise procedure, only the AI-SKT remained as a statistically significant variable of the model (β = 0.163, p = 0.028) (see Table 2; Fig. 1).

### Correlations between GM volume and AI-SKT performance: VBM analyses

As the AI-SKT was the only executive test with a statistically significant association with Aβ deposition in the former analysis, it was the only test selected for VBM. Higher GM volume in the left frontal inferior, parietal, angular, and anterior cingulate was found related to worse AI-SKT scores (Table 3). Moreover, lower GM volume in the bilateral hippocampus and the left frontal, Rolandic, and precentral regions was found associated with worse AI-SKT performance. Anatomical regions and statistics from both contrasts are detailed in Table 3 (Fig. 2).

## Discussion

The results of the present study reinforce the importance of assessing executive functioning in the early detection of AD in individuals with SCD. We found lower performance on the AI-SKT executive subtest to be related to higher brain Aβ deposition. For the rest of the executive function tests no association between brain Aβ deposition and performance was found. This finding may be explained by the fact that these tests assess different cognitive processes related to executive functions such as working memory, cognitive flexibility or inhibition ability24,25. Additionally, low AI-SKT scores were associated with higher GM volume in the left frontal inferior, parietal, angular, and anterior cingulate areas and lower GM volume in the bilateral hippocampus and left frontal regions.

In individuals with SCD, we found poorer automatic inhibition ability related to higher brain Aβ deposition. Consistent with this result, Snitz et al.18 reported that Aβ-positive older adults without dementia showed evidence of a greater decline in executive function over an interval of 7–9 years prior to neuroimaging, compared with Aβ-negative individuals. Moreover, in a cross-sectional study using CSF as a marker, Harrington et al.23 found subtle executive dysfunction as one of the first deficits in preclinical AD.

With regard to the structural MRI analysis, our data showed that worse AI-SKT subtest scores were related to lower volume of the bilateral hippocampus and left frontal regions (including the frontal inferior operculum, rolandic operculum, and precentral areas). It is well-known that the hippocampus is one of the earliest brain regions affected in AD according to the topographic progression of tau deposits and neurodegeneration26,27. In this sense, a decreased hippocampal volume is a well-established neuroimaging biomarker linked to the initial stages of AD28,29 and described as a predictor of conversion from MCI to dementia30. Our findings are consistent with those of other studies that have reported hippocampal volume changes in SCD6,31,32. Also in line with our findings , an association between a lower volume of hippocampus and the performance of executive functions has been described33. With regard to the association between worse AI-SKT subtest performance and lower GM volume in the left frontal regions, our results are consistent with those of previous studies in which set-shifting task performance was found to be related to the activation of the frontal inferior and precentral regions34.

Interestingly, we found a negative correlation between worse AI-SKT performance and higher volume in brain association areas (angular gyrus, cingulum anterior, corpus callosum) and the inferior frontal and parietal regions. Chételat et al.35 reported increased temporal lobe volume in healthy individuals who had high amyloid burden compared to those with low Aβ deposition. It has been argued that this may reflect a compensatory response to the local amyloid deposition. Another interpretation for the current findings might be related to the existence of a non-linear pattern of GM volume changes associated with early stages of AD. Gispert et al.36 analyzed the association between GM volume and AD CSF biomarkers and identified a nonlinear relationship between GM volume reduction and the progression of AD pathology.

We acknowledge that the present study has strengths and limitations. First, it is a cross-sectional study, so the results only reflect data from a particular point in time (the baseline visit of the study). As FACEHBI includes a follow-up with repeated cognitive testing, PET-FBB, and brain MRI every two years, we plan to continue our research about the longitudinal relationship between executive functions and AD biomarkers. The FACEHBI is a single-center study, that is, participants were exclusively recruited from Fundació ACE’s memory clinic, with all cognitive and biomarkers measures performed, collected, and processed in a homogeneous way, which guarantees data uniformity. This study was focused on determining whether a relationship between performance on executive tests and AD biomarkers could be detected, in analogy with previous literature on the relationship between memory tests and AD biomarkers. Therefore, the relationships of amyloid and GM volume with cognitive areas other than executive functions have not been explored in the work presented here.

The ultimate aim of the present study was to identify which executive function test may prove to be a sensitive tool to detect early markers of AD such as elevated amyloid burden or GM volume changes. However, the results of the present study might be interpreted with caution because it was performed in individuals with SCD with relatively preserved executive performance and low Aβ deposition in the brain. It will be important to check how these executive tests perform in different memory clinics and in community-based studies. Further studies are needed to find economical and noninvasive tools that could enable AD risk prediction in cognitively healthy individuals. To achieve this, we consider it crucial to perform additional longitudinal analyses to deepen our knowledge of preclinical AD.

In conclusion, in SCD individuals, a decline in automatic inhibition ability has been found to be associated with higher cerebral Aβ levels and lower volume in the hippocampus and frontal regions. These findings reinforce the importance of assessing executive functioning in individuals with SCD.

## Methods

### Subjects

From a cohort of 200 SCD subjects, 5 were excluded due to acquisition or movement artifacts in MRI or PET data. The resulting sample of 195 individuals had completed data from executive tests and was included in the study. The FACEHBI inclusion criteria are described in detail elsewhere22. In brief, they include: age older than 49 years old, literate with at least elementary school (or at least six years of formal education), Subjective Cognitive Complaints defined as a score of ≥ 8 on the Spanish Modified Questionnaire of Memory Failures in Everyday (MFE-30)37; a preserved performance on the Mini-mental State Examination (MMSE ≥ 27)38,39; a strictly normal performance for age and education in a comprehensive neuropsychological battery of Fundació ACE (NBACE)40; a Clinical Dementia Rating Score (CDR) of 041; and without relevant depressive/anxiety symptoms on the Spanish version of the Hospital Anxiety and Depression Scale (HADS < 11)42, or another psychiatric illness. Exclusion criteria were: evidence of impairment in daily life activities, history of alcoholism and epilepsy; renal or liver failure; and presence of severe auditory or visual abnormalities that could affect neuropsychological test performance (see Rodriguez-Gomez et al., for details)22.

All patients underwent a complete neurological and neuropsychological examination, a set of self-administered questionnaires and a battery of multimodal biomarkers, including APOE genotyping, an MRI protocol and an 18F-Florbetaben PET (FBB-PET)22. Invalid FBB-PET and MRI data (i.e., acquisition or movement artifacts) were excluded from the current study.

### MRI and FBB-PET acquisitions

All MRI scans were acquired prior to FBB-PET. MRI was performed on a 1.5 T Siemens Magnetom Aera (Erlangen, Germany) using a 32-channel head coil. T1-weighted images were acquired using a rapid acquisition gradient-echo 3-D MPRAGE sequence with the following parameters: TR 2200 ms, TE 2.66 ms, TI 900 ms, slip angle 8º, FOV 250 mm, slice thickness 1 mm, and isotropic voxel size 1 × 1 × 1 mm. In addition, all participants underwent an axial T2-weighted, 3-D isotropic FLAIR and axial T2*-weighted sequences to detect significant vascular pathology or microbleeds.

FBB-PET images were acquired in a 90-day window after the baseline visit in a Siemens Biograph molecular-CT machine. Four FBB-PET scans of 5 min were acquired 90 min post IV injection of 300 Mbq of 18F-Florbetaben radio tracer (NeuraCeq), provided by Life Molecular Imaging (formerly Piramal Imaging).

### Standard uptake value ratio

First, MRI cortical and subcortical segmentation of the T1-weighted images was carried out with Freesurfer 5.3 (https://surfer.nmr.mgh.harvard.edu/). FBB-PET scans were processed with the FSL 5.0 package (https://fsl.fmrib.ox.ac.uk/fsl/fslwiki). The FBB-PET images were coregistered onto structural images, and then the standard uptake value ratio (SUVR) was determined as the mean value of the cortical regions segmented on MRI, and normalized by the cerebellum as the reference region.

### Voxel-based morphometry

A voxel-based morphometry (VBM)50 was conducted with the T1-weighted images. First, data were visually inspected for artefacts and manually centered in the anterior commissure (AC). Next, segmentation into grey matter (GM), white matter (WM) and other tissues was carried out using SPM12 (https://www.fil.ion.ucl.ac.uk/spm/software/spm12/). GM data were normalized to the MNI space according to the Dartel technique51, also implemented in SPM12. Finally, Jacobian-scaled GM images were smoothed through an isotropic Gaussian kernel using 6mm3 FWHM.

### Statistical analysis

#### Clinical variables in association with SUVR

Statistical analysis was performed using SPSS (version 26, SPSS Inc., Chicago, IL). All data were examined for normality, skew, and range restriction. SUVR was log10 transformed to normalize its distribution. Correlations or T-test were calculated for the demographic with global SUVR. In order to determine which executive functions (Rule Shift Cards from BADS, Digit Span Backwards and Similarities from WAIS-III, Trail Making Test A and B, Automatic Inhibition subtest of the Syndrome Kurz Test and letter, semantic, and verb verbal fluency tests) were statistically associated with global SUVR a multiple regression analysis was executed. Stepwise procedure was used to identify the final significant variables. Age was here included as an adjusting variable.

#### Topological GM correlates of executive test performances

Next, those executive function test scores which correlated to amyloid burden in the former step were explored separately in association with GM volume, using the VBM voxel-wise approach. The statistical associations between several variables (age, sex, SUVR, years of formal education and APOE status) and executive tests scores were assessed to include those variables with a significant association into the model. As the formula below shows, the final model design included age, sex and years of formal education as covariates. Statistical designs were also corrected for Total Intracranial Volume (TIV) as a global, and μ indicates the mean.

$$\upmu + {\text{sex}} + {\text{age}} + {\text{years}}\,{\text{of}}\,{\text{education}} + {\text{test}}\,{\text{performance}} + {\text{TIV}}$$

Statistical parametric maps were thresholded using uncorrected p < 0.005, and an extent threshold of k = 100 voxels per cluster.

### Ethical standards

All the participants signed written informed consent prior to any evaluation. The FACEHBI protocol received approval from the ethics committees of Hospital Clínic i Provincial in Barcelona, Spain (EudraCT number 2014-00079-38). The referral center ethics committee approved patient recruitment, and collection protocols were in accordance with ethical standards according to the World Medical Association Declaration of Helsinki—Ethical Principles for Medical Research Involving Human Subjects.

## Data availability

Data used for this study are available from the corresponding author on reasonable request.

## References

1. 1.

Jessen, F. et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease and Subjective Cognitive Decline Initiative (SCD-I) Working Group. Alzheimers Dement 10, 844–852 (2014).

2. 2.

Mitchell, D. Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: Meta-analysis. Acta Psychiatr. Scand. 130, 439–451 (2014).

3. 3.

Amariglio, R. E. et al. Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia 50, 2880–2886 (2012).

4. 4.

Perrotin, A., Mormino, E. C., Madison, C. M., Hayenga, A. O. & Jagust, W. J. Subjective cognition and amyloid deposition imaging. Arch. Neurol. 62, 223–229 (2012).

5. 5.

Jessen, F. et al. Volume reduction of the entorhinal cortex in subjective memory impairment. Neurobiol. Aging 27, 1751–1756 (2006).

6. 6.

Van Norden, A. G. W. et al. Subjective cognitive failures and hippocampal volume in elderly with white matter lesions. Neurology 71, 1152–1159 (2008).

7. 7.

Mosconi, L. et al. Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. Biol. Psychiatry 63, 609–618 (2008).

8. 8.

Scheef, L. et al. Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment. Neurology 79, 1332–1339 (2012).

9. 9.

Buckley, R. F. et al. Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer’s disease. Alzheimer’s Dement. 12, 1–9 (2016).

10. 10.

Baker, J. E. et al. Cognitive impairment and decline in cognitively normal older adults with high amyloid-β: A meta-analysis. Alzheimer’s Dement. Diagnosis. Assess. Dis. Monit. 6, 108–121 (2017).

11. 11.

Hedden, T., Oh, H., Younger, A. P. & Tanu Patel, B. A. Meta-analysis of amyloid-cognition relations in cognitively normal older adults. Am. Acad. Neurol. 80, 1341–1348 (2013).

12. 12.

Sanabria, A. et al. The Spanish version of Face-Name Associative Memory Exam (S-FNAME) performance is related to amyloid burden in Subjective Cognitive Decline. Sci. Rep. 28, 1–9 (2018).

13. 13.

Chen, Y. et al. Progression from normal cognition to mild cognitive impairment in a diverse clinic-based and community-based elderly cohort. Alzheimer’s Dement. 13, 399–405 (2017).

14. 14.

Ewers, M. et al. Prediction of conversion from mild cognitive impairment to Alzheimer’s disease dementia based upon biomarkers and neuropsychological test performance and in collaboration with the North American Alzheimer’s Disease Neuroimaging Initiative (ADNI) NIH Publi. Neurobiol. Aging 33, 1203–1214 (2012).

15. 15.

Alegret, M. et al. The role of verb fluency in the detection of early cognitive impairment in Alzheimer’s disease. J. Alzheimer’s Dis. 62, 611–619 (2018).

16. 16.

Fonseca, J. A. S. et al. Factors that predict cognitive decline in patients with subjective cognitive impairment. Int. Psychogeriatr. 27, 1671–1677 (2015).

17. 17.

Chen, P., Ratcliff, G. & Belle, S. H. Patterns of cognitive decline in presymptomatic Alzheimer disease. Arch. Gen. Psychiatry 58, 853–858 (2001).

18. 18.

Snitz, B. E. et al. Cognitive trajectories associated with β-amyloid deposition in the oldest-old without dementia. Neurology 80, 1378–1384 (2013).

19. 19.

Oh, H. et al. β-amyloid affects frontal and posterior brain networks in normal aging. Neuroimage 54, 1887–1895 (2011).

20. 20.

Chételat, G. et al. Relationship between atrophy and β-amyloid deposition in Alzheimer’s disease. Ann. Neurol. 67, 317–324 (2010).

21. 21.

Sánchez-Benavides, G. et al. Brain and cognitive correlates of subjective cognitive decline-plus features in a population-based cohort. Alzheimers Res. Ther. 10, 123 (2018).

22. 22.

Rodriguez-Gomez, O. et al. FACEHBI: A prospective study of risk factors, biomarkers and cognition in a cohort of individuals with subjective cognitive decline. Study Rationale and Research Protocols. Jpad 3, 1–9 (2016).

23. 23.

Harrington, M. G. et al. Executive function changes before memory in preclinical Alzheimer’s pathology: A prospective, cross-sectional, case control study. PLoS ONE 8, 1–12 (2013).

24. 24.

Baddeley, A. The central executive: A concept and some misconceptions. J. Int. Neuropsychol. Soc. 4, 523–526 (1998).

25. 25.

Stuss, D. T. & Alexander, M. P. Executive functions and the frontal lobes: A conceptual view. Psychol. Res. 63, 289–298 (2000).

26. 26.

Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239–259 (1991).

27. 27.

Braak, H. & Braak, E. Evolution of the neuropathology of Alzheimer’s disease. Acta Neurol. Scand. Suppl. 165, 3–12 (1996).

28. 28.

Frisoni, G. B., Fox, N. C., Jack, C. R., Scheltens, P. & Thompson, P. M. The clinical use of structural MRI in Alzheimer disease. Nat. Rev. Neurol. 6, 67–77 (2010).

29. 29.

Harper, L. et al. Patterns of atrophy in pathologically confirmed dementias: A voxelwise analysis. J. Neurol. Neurosurg. Psychiatry 5, 1–9 (2017).

30. 30.

Devanand, D. P. et al. Hippocampal and entorhinal atrophy in mild cognitive impairment: Prediction of Alzheimer disease. Neurology 68, 828–836 (2007).

31. 31.

Perrotin, A. et al. Hippocampal subfield volumetry and 3D surface mapping in subjective cognitive decline. J. Alzheimer’s Dis. 48, S141–S150 (2015).

32. 32.

Stewart, R. et al. Neuroimaging correlates of subjective memory deficits in a community population. Neurology 70, 1601–1607 (2008).

33. 33.

Nagata, T. et al. Association between executive dysfunction and hippocampal volume in Alzheimer’s disease. Int. Psychogeriatrics 23, 764–771 (2011).

34. 34.

Brass, M. The role of the inferior frontal junction area in cognitive control. Trends Cogn. Sci. 9, 312–314 (2005).

35. 35.

Chételat, G. et al. Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain 133, 3349–3358 (2010).

36. 36.

Gispert, J. D. et al. Nonlinear cerebral atrophy patterns across the Alzheimer’s Disease continuum: Impact of APOE4 genotype. Neurobiol. Aging 36, 2687–2701 (2015).

37. 37.

Lozoya-Delgado, P., de León, J. M. R. & Pedrero-Pérez, E. J. Validation of a cognitive complaints questionnaire for young adults: The relation between subjective memory complaints, prefrontal symptoms and perceived stress. Rev. Neurol. 54, 137–150 (2012).

38. 38.

Blesa, R. et al. Clinical validity of the ‘mini-mental state’ for Spanish speaking communities. Neuropsychologia 39, 1150–1157 (2001).

39. 39.

Folstein, M. F., Folstein, S. E. & McHugh, P. R. ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatry Res. 12, 189–98 (1975).

40. 40.

Alegret, M. et al. Normative data of a brief neuropsychological battery for Spanish individuals older than 49. J. Clin. Exp. Neuropsychol. 34, 209–219 (2012).

41. 41.

Morris, J. C. The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 43, 2412–2412 (1993).

42. 42.

Snaith, R. P. & Zigmond, A. S. The hospital anxiety and depression scale. BMJ 292, 344–344 (1986).

43. 43.

Reitan, R. M. & Wolfson, D. The Halstead–Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation (Neuropsychology Press, London, 1985).

44. 44.

Wilson, B. A., Alderman, N., Burgess, P. W., Emslie, H. & Evans, J. J. Behavioural Assessment of the Dysexecutive Syndrome (BADS) (Thames Valley Test Company, London, 1996).

45. 45.

Piatt, A. L., Fields, J. A., Paolo, A. M. & Tro, A. I. Action (verb naming) fuency as an executive function measure: Convergent and divergent evidence of validity. Neuropsychologia 37, 1499–1503 (1999).

46. 46.

Erzigkeit, H. The SKT: A short cognitive performance test as an instrument for the assessment of clinical efficacy of cognitive enhancers. In Diagnosis and Treatment of Senile Dementia (eds Berenger, M. & Reisberg, B.) 164–174 (Springer, Berlin, 1989).

47. 47.

Artiola, L., Hermosillo, D., Heaton, R. & Pardee, R. E. Manual de normas y procedimientos para la batería neuropsicológica en español [Manual of Norms and Procedures for the Spanish Neuropsychological Battery] (M Press, Tucson, 1999).

48. 48.

Goodglass, H. & Kaplan, E. The Assessment of Aphasia and Related. 2 Disorders (Lea and Febiger, Philadelphia, 1983).

49. 49.

Wechsler, D. WAIS–III Wechsler Adult Intelligence Scale-Third Edition Technical manual (The Psychological Corporation, San Antonio, 1997).

50. 50.

Ashburner, J. & Friston, K. J. Voxel-based morphometry. The Methods 821, 805–821 (2000).

51. 51.

Ashburner, J. A fast diffeomorphic image registration algorithm. Neuroimage 38, 95–113 (2007).

## Acknowledgements

We would like to thank all FACEHBI participants for their generosity and their trust in our institution.

## Funding

This work was funded by Grifols SA, Life Molecular Imaging, Laboratorios Echevarne, Araclon Biotech, and Fundació ACE Memory Clinic, and was supported by the Spanish Ministry of Health from Instituto de Salud Carlos III (Madrid) (FISS PI10/00945) and by the Agència d’Avaluació de Tecnologia i Recerca Mèdiques. Departament de Salut de la Generalitat de Catalunya (Health Department of the Catalan Government) (390) and by funds from Fundació ACE, Institut Català de Neurociències Aplicades. Fundació ACE collaborates with the Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED, Spain) and is one of the participating centers of the Dementia Genetics Spanish Consortium (DEGESCO).

## Author information

Authors

### Contributions

A.P., G.M., and M.A., contributed to the design, acquisition, analysis, and interpretation of data; drafting; and writing the article. M.B., A.R., A.B., and Ll.T. conceived and designed the study. O.R., M.A., A.S., A.E., G.O., C.A., M.M, I.H., A.P., M.R., L.V., A.M., S.G, and J.P.T. contributed to the design and enrolled patients in the Fundació ACE. S.V. analyzed the data, and G.M. and F.L, F.C, A.V., and M.G. contributed to neuroimaging processing and image analysis. M.B. and A.R. obtained funding. The FACEHBI group study critically reviewed the manuscript and approved the final version prior to submission.

### Corresponding author

Correspondence to Montserrat Alegret.

## Ethics declarations

### Competing interests

Dr. Mercè Boada has consulted for Araclon, Avid, Grifols, Lilly, Nutricia, Roche, Eisai and Servier. She received fees from lectures and funds for research from Araclon, Biogen, Grifols, Nutricia, Roche and Servier. She has not received personal compensations from these organizations. The other authors declare no competing financial interests.

### Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Rights and permissions

Reprints and Permissions

Pérez-Cordón, A., Monté-Rubio, G., Sanabria, A. et al. Subtle executive deficits are associated with higher brain amyloid burden and lower cortical volume in subjective cognitive decline: the FACEHBI cohort. Sci Rep 10, 17721 (2020). https://doi.org/10.1038/s41598-020-74704-7

• Accepted:

• Published: